Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第八次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the company's third quarter 2022 equity distribution plan, referencing the unaudited 2022 third quarter report. It discusses the dividend proposal and confirms compliance with laws and company regulations. The document is short (844 characters) and is a formal opinion related to a board meeting matter, not a full financial report or earnings release. It does not contain actual financial statements or detailed financial data but rather an opinion on a board resolution. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to board matters and dividend proposals but not the dividend notice itself or a full report.
2022-10-26 Chinese
关于公司获得国际发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (757 characters) about the receipt of a patent certificate from the Dutch Patent Office. It includes details about the patent and its impact on the company but does not contain any financial data, regulatory filings, or report attachments. It is not a financial report, management change, voting result, or any other specific filing type. It is a general regulatory announcement about intellectual property. Therefore, it fits best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2022-10-17 Chinese
关于公司收到政府上市补贴资金的公告
Capital/Financing Update Classification · 90% confidence The document is a short announcement (468 characters) regarding the receipt of a government subsidy related to listing support funds. It references accounting treatment to be confirmed by an audit but does not contain any financial statements or detailed financial data. It is not a full report but a regulatory announcement about a financing-related event (government subsidy). Given the content and length, it fits best under Capital/Financing Update (CAP).
2022-09-28 Chinese
投资者关系活动记录表
Investor Presentation Classification · 90% confidence The document is an investor relations activity record from Guangdong Driving Force Biotechnology Group Co., Ltd. It details a Q&A session held via an online platform on September 22, 2022, where company representatives answered investor questions about the company's half-year performance, stock options, core technical staff, shareholder share reduction, and business outlook. The content is a record of an investor relations event rather than a formal financial report or earnings release. It does not contain financial statements or detailed financial data but rather a summary of communication with investors. This fits the category of Investor Presentation (IP), which includes detailed presentations or communications focusing on financials, strategy, and market position, often including Q&A sessions with investors.
2022-09-22 Chinese
第三届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Guangdong Driving Force Biotechnology Group Co., Ltd. It details the meeting date, attendance, and resolutions passed, including approval of the company's 2022 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report as being published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is not the report itself but a meeting resolution announcement. The content is about the Supervisory Board meeting decisions, not the full financial report or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim Report (IR) or Annual Report (10-K). The document length is short and it does not contain substantive financial data itself, supporting this classification.
2022-08-23 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '广东驱动力生物科技集团股份有限公司 2022 年半年度报告' which translates to 'Guangdong Drive Bio-tech Group Co., Ltd. 2022 Semi-Annual Report'. It contains detailed financial data, including income, profit, assets, liabilities, and operational metrics for the period January 1, 2022 to June 30, 2022. The document includes sections on company overview, accounting data, business overview, risk factors, and financial analysis. It explicitly states it is a '半年度报告' (half-year report) and includes comprehensive financial statements and management discussion. The length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.